Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMC-001 |
| Synonyms | |
| Therapy Description |
IMC-001 is an anti-PD-L1 (CD274) antibody that stimulates the anti-tumor response (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMC-001 | IMC001|IMC 001|STI 3031 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | IMC-001 is an anti-PD-L1 (CD274) antibody that stimulates the anti-tumor response (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05393713 | Phase I | IMC-001 | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for the Treatment of In-Transit Melanoma, The Sofusa-2 Study | Terminated | USA | 0 |